AUM Biosciences competitors & alternatives

Life Sciences

OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.

Apeiron TherapeuticsBiotechnology

71% match

Biotechnology

Apeiron Therapeutics is a clinical-stage biopharmaceutical and precision oncology company focused on developing biomarker-driven therapeutics for cancer.

Aptose Biosciences Inc.APTOF · BiotechUnited States

70% matchPublic

Similar biotech company

Aptose Biosciences Inc. is a clinical-stage biotechnology company that develops small molecule cancer therapeutics, focusing on precision medicines for hematologic malignancies. The company's product pipeline features investigational drug candidates such as tuspetinib and luxeptinib, which are designed to treat conditions like acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and B-cell malignancies.

Alterome Therapeutics, Inc.BiotechnologyUnited States

70% matchPrivate

Biotechnology

Alterome Therapeutics, Inc. is a clinical-stage precision oncology company headquartered in San Diego, California, founded in 2021. The privately held biotech firm focuses on developing targeted therapies to address genomically defined cancer drivers and intractable oncological targets.

TESSELLATE THERAPEUTICS INCBiotechnologyUnited States

70% matchPrivate

Biotechnology

Tessellate Bio is a biotechnology company that develops precision oncology medicines by exploring synthetic lethal interactions beyond homologous recombination deficiency. The company integrates biomarker discovery and companion diagnostics into its research programs to create first-in-class treatments for hard-to-treat cancers.

Orum TherapeuticsBiotechUnited States

70% match

Similar biotech company

Orum Therapeutics is a biotechnology research company specializing in the development of targeted protein degraders for precision oncology using its TPD² approach. The company is headquartered in Daejeon, South Korea, with additional offices in Boston, Massachusetts.

A2 Biotherapeutics, Inc.BiotechnologyUnited States

70% matchPrivate

Biotechnology

A2 Biotherapeutics, Inc. is a clinical-stage biotechnology research company headquartered in Agoura Hills, California. The company develops precision T-cell therapies designed to target solid tumors while sparing healthy tissue.

Edison Oncology Holding CorpBiotechnologyUnited States

70% matchPrivate

Biotechnology

Edison Oncology Holding Corp is a clinical-stage biopharmaceutical company that develops first-in-class, small-molecule, biomarker-driven therapies to target major cancer markets. The company identifies, acquires, and advances underdeveloped drug candidates to address critical unmet needs for cancer patients with specific genetic mutations.

Core BiomedicineBiotechnology

68% match

Biotechnology

Core Biomedicine is a preclinical-stage biotechnology and pharmaceutical manufacturing company pioneering lineage-based precision oncology therapeutics.

Similar biotech company

Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.

Biotechnology

DCx Biotherapeutics is a Canadian preclinical-stage biotechnology company developing precision oncology therapeutics and precision drug conjugates to target genetically defined cancers. The company focuses on addressing root drivers and key cellular interdependencies of cancer lesions.

EVOPOINT BIOSCIENCES CO.,LTD.688837 · BiotechChina

67% matchPublic

Similar biotech company

EVOPOINT BIOSCIENCES CO., LTD. is an innovation-driven pharmaceutical company that focuses on precision oncology, multi-drug resistant bacterial infections, and metabolic diseases. Utilizing core platforms such as small molecule targeted drug development, complex antibody drug development, and targeted protein degradation, the company researches and develops innovative drug pipelines to provide treatment solutions for patients globally.